1.
Gentile G, Mastroluca D, Ruggenenti P, Remuzzi G: Novel effective drugs for diabetic
kidney disease? or not? Expert Opinion on Emerging Drugs 2014, 19(4):571-601.
2.
Bell S, Fletcher EH, Brady I, Looker HC, Levin D, Joss N, Traynor JP, Metcalfe W,
Conway B, Livingstone S et al: End-stage renal disease and survival in people with
diabetes: a national database linkage study. QJM 2015, 108(2):127-134.
3.
Kato M, Natarajan R: Diabetic nephropathy--emerging epigenetic mechanisms. Nature
Reviews Nephrology 2014, 10(9):517-530.
4.
de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan
D, Lambers Heerspink HJ, Makino H et al: The endothelin antagonist atrasentan lowers
residual albuminuria in patients with type 2 diabetic nephropathy. Journal of the
American Society of Nephrology : JASN 2014, 25(5):1083-1093.
5.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman
DW, Kohan D, Makino H, McMurray JJV et al: Atrasentan and renal events in patients
with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised,
placebo-controlled trial. Lancet (London, England) 2019, 393(10184):1937-1947.
6.
Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar
N, Whincup PH, Mukamal KJ, Gillum RF, Holme I et al: Diabetes mellitus, fasting
glucose, and risk of cause-specific death. The New England Journal of Medicine 2011,
364(9):829-841.
7.
Cao Z, Cooper ME: Pathogenesis of diabetic nephropathy. Journal of Diabetes
Investigation 2011, 2(4):243-247.
8.
Kumar Pasupulati A, Chitra PS, Reddy GB: Advanced glycation end products mediated
84
cellular and molecular events in the pathology of diabetic nephropathy. Biomolecular
Concepts 2016, 7(5-6):293-309.
9.
Randi EB, Vervaet B, Tsachaki M, Porto E, Vermeylen S, Lindenmeyer MT, Thuy LTT,
Cohen CD, Devuyst O, Kistler AD et al: The antioxidative role of cytoglobin in
podocytes: Implications for a role in chronic kidney disease. Antioxidants & redox
signaling 2020, 32(16):1155-1171.
10.
Hajhosseiny R, Khavandi K, Jivraj N, Mashayekhi S, Goldsmith DJ, Malik RA: Have we
reached the limits for the treatment of diabetic nephropathy? Expert Opinion on
Investigational Drugs 2014, 23(4):511-522.
11.
Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC: Advances in targeting
cyclic nucleotide phosphodiesterases. Nature Reviews Drug Discovery 2014, 13(4):290314.
12.
Conti M, Beavo J: Biochemistry and physiology of cyclic nucleotide phosphodiesterases:
essential components in cyclic nucleotide signaling. Annual Review of Biochemistry 2007,
76:481-511.
13.
Francis SH, Blount MA, Corbin JD: Mammalian cyclic nucleotide phosphodiesterases:
molecular mechanisms and physiological functions. Physiological Reviews 2011,
91(2):651-690.
14.
Baillie GS, Tejeda GS, Kelly MP: Therapeutic targeting of 3',5'-cyclic nucleotide
phosphodiesterases: inhibition and beyond. Nature Reviews Drug Discovery 2019,
18(10):770-796.
15.
Wang P, Wu P, Ohleth KM, Egan RW, Billah MM: Phosphodiesterase 4B2 is the
predominant phosphodiesterase species and undergoes differential regulation of gene
expression in human monocytes and neutrophils. Molecular Pharmacology 1999,
85
56(1):170-174.
16.
Totani L, Amore C, Piccoli A, Dell'Elba G, Di Santo A, Plebani R, Pecce R, Martelli N,
Rossi A, Ranucci S et al: Type-4 phosphodiesterase (PDE4) blockade reduces NETosis
in cystic fibrosis. Frontiers in Pharmacology 2021, 12:702677.
17.
Zebda R, Paller AS: Phosphodiesterase 4 inhibitors. Journal of the American Academy of
Dermatology 2018, 78(3 Suppl 1):S43-s52.
18.
Peng T, Qi B, He J, Ke H, Shi J: Advances in the development of phosphodiesterase-4
inhibitors. Journal of Medicinal Chemistry 2020, 63(19):10594-10617.
19.
Vollert S, Kaessner N, Heuser A, Hanauer G, Dieckmann A, Knaack D, Kley HP, Beume
R, Weiss-Haljiti C: The glucose-lowering effects of the PDE4 inhibitors roflumilast and
roflumilast-N-oxide in db/db mice. Diabetologia 2012, 55(10):2779-2788.
20.
Wouters EF, Bredenbröker D, Teichmann P, Brose M, Rabe KF, Fabbri LM, Göke B:
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients
with treatment-naive, newly diagnosed type 2 diabetes mellitus. The Journal of Clinical
Endocrinology and Metabolism 2012, 97(9):E1720-1725.
21.
McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G: The effect of
pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. American
Journal of Kidney Diseases : the official journal of the National Kidney Foundation 2008,
52(3):454-463.
22.
Dousa TP: Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and
pathophysiology of the kidney. Kidney International 1999, 55(1):29-62.
23.
Jonassen TE, Graebe M, Promeneur D, Nielsen S, Christensen S, Olsen NV:
Lipopolysaccharide-induced acute renal failure in conscious rats: effects of specific
phosphodiesterase type 3 and 4 inhibition. The Journal of Pharmacology and
86
Experimental Therapeutics 2002, 303(1):364-374.
24.
Matousovic K, Tsuboi Y, Walker H, Grande JP, Dousa TP: Inhibitors of cyclic nucleotide
phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid.
The Journal of Laboratory and Clinical Medicine 1997, 130(5):487-495.
25.
Insel PA, Murray F, Yokoyama U, Romano S, Yun H, Brown L, Snead A, Lu D,
Aroonsakool N: cAMP and Epac in the regulation of tissue fibrosis. British Journal of
Pharmacology 2012, 166(2):447-456.
26.
Togo S, Liu X, Wang X, Sugiura H, Kamio K, Kawasaki S, Kobayashi T, Ertl RF, Ahn Y,
Holz O et al: PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF{beta}1-stimulated fibroblasts. American Journal of Physiology Lung cellular and
Molecular Physiology 2009, 296(6):L959-969.
27.
Sisson TH, Christensen PJ, Muraki Y, Dils AJ, Chibucos L, Subbotina N, Tohyama K,
Horowitz JC, Matsuo T, Bailie M et al: Phosphodiesterase 4 inhibition reduces lung
fibrosis following targeted type II alveolar epithelial cell injury. Physiological Reports
2018, 6(12):e13753.
28.
Xu M, Yu X, Meng X, Huang S, Zhang Y, Zhang A, Jia Z: Inhibition of PDE4/PDE4B
improves renal function and ameliorates inflammation in cisplatin-induced acute kidney
injury. American Journal of Physiology Renal Physiology 2020, 318(3):F576-f588.
29.
Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J,
Moore KJ, Breitbart RE et al: Evidence that the diabetes gene encodes the leptin receptor:
identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996,
84(3):491-495.
30.
Dubern B, Clement K: Leptin and leptin receptor-related monogenic obesity. Biochimie
2012, 94(10):2111-2115.
87
31.
Tomino Y: Lessons From the KK-Ay mouse, a spontaneous animal model for the
treatment of human type 2 diabetic nephropathy. Nephro-Urology Monthly 2012,
4(3):524-529.
32.
Nio Y, Ookawara M, Yamasaki M, Hanauer G, Tohyama K, Shibata S, Sano T, Shimizu
F, Anayama H, Hazama M et al: Ameliorative effect of phosphodiesterase 4 and 5
inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKA(y)
mice. FASEB Journal : official publication of the Federation of American Societies for
Experimental Biology 2020, 34(11):14997-15014.
33.
Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K: Diabetes and kidney disease:
role of oxidative stress. Antioxidants & Redox Signaling 2016, 25(12):657-684.
34.
Chang JM, Kuo MC, Kuo HT, Chiu YW, Chen HC: Increased glomerular and
extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. The
Journal of Laboratory and Clinical Medicine 2005, 146(4):210-215.
35.
Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M: Hypertension and kidneys:
unraveling complex molecular mechanisms underlying hypertensive renal damage.
Journal of Human Hypertension 2014, 28(2):74-79.
36.
Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. Journal of the
American Society of Nephrology : JASN 2010, 21(11):1819-1834.
37.
Liu Y: Cellular and molecular mechanisms of renal fibrosis. Nature Reviews Nephrology
2011, 7(12):684-696.
38.
Chertow GM, Beddhu S, Lewis JB, Toto RD, Cheung AK: Managing hypertension in
patients with CKD: A marathon, not a sprint. Journal of the American Society of
Nephrology : JASN 2016, 27(1):40-43.
39.
Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F,
88
Manganiello V, Stratakis CA: Clinical and molecular genetics of the phosphodiesterases
(PDEs). Endocrine Reviews 2014, 35(2):195-233.
40.
Sanz MJ, Cortijo J, Morcillo EJ: PDE4 inhibitors as new anti-inflammatory drugs: effects
on cell trafficking and cell adhesion molecules expression. Pharmacology &
Therapeutics 2005, 106(3):269-297.
41.
Giembycz MA, Field SK: Roflumilast: first phosphodiesterase 4 inhibitor approved for
treatment of COPD. Drug Design, Development and Therapy 2010, 4:147-158.
42.
Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Espinoza F, Pons H, Vaziri ND:
Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal
damage. Kidney International 2005, 68(5):2131-2142.
43.
Kim KH, Kim HK, Hwang IC, Cho HJ, Je N, Kwon OM, Choi SJ, Lee SP, Kim YJ, Sohn
DW: PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions
and exercise capacity in patients with chronic heart failure with reduced ejection fraction;
A 12-week, randomized, double-blind, placebo-controlled trial. American Heart Journal
2015, 169(6):813-822.e813.
44.
Fang L, Radovits T, Szabó G, Mózes MM, Rosivall L, Kökény G: Selective
phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1
diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in
podocytes. Nephrology, dialysis, Transplantation 2013, 28(7):1751-1761.
45.
Mátyás C, Németh BT, Oláh A, Török M, Ruppert M, Kellermayer D, Barta BA, Szabó
G, Kökény G, Horváth EM et al: Prevention of the development of heart failure with
preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with
type 2 diabetes. European Journal of Heart Failure 2017, 19(3):326-336.
46.
Radovits T, Bömicke T, Kökény G, Arif R, Loganathan S, Kécsán K, Korkmaz S, Barnucz
89
E, Sandner P, Karck M et al: The phosphodiesterase-5 inhibitor vardenafil improves
cardiovascular dysfunction in experimental diabetes mellitus. British Journal of
Pharmacology 2009, 156(6):909-919.
47.
Czirok S, Fang L, Radovits T, Szabó G, Szénási G, Rosivall L, Merkely B, Kökény G:
Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß
expression in type-1 diabetic rats. Scientific Reports 2017, 7(1):11218.
48.
Pofi R, Fiore D, De Gaetano R, Panio G, Gianfrilli D, Pozza C, Barbagallo F, Xiang YK,
Giannakakis K, Morano S et al: Phosphodiesterase-5 inhibition preserves renal
hemodynamics and function in mice with diabetic kidney disease by modulating miR-22
and BMP7. Scientific Reports 2017, 7:44584.
49.
Mehanna OM, El Askary A, Al-Shehri S, El-Esawy B: Effect of phosphodiesterase
inhibitors on renal functions and oxidant/antioxidant parameters in streptozocin-induced
diabetic rats. Archives of Physiology and Biochemistry 2018, 124(5):424-429.
50.
Iordache AM, Buga AM, Albulescu D, Vasile RC, Mitrut R, Georgiadis G, Zisis IE,
Mamoulakis C, Tsatsakis A, Docea AO et al: Phosphodiesterase-5 inhibitors ameliorate
structural kidney damage in a rat model of contrast-induced nephropathy. Food and
Chemical Toxicology 2020, 143:111535.
51.
Ruzicka M, Hiremath S, Steiner S, Helis E, Szczotka A, Baker P, Fodor G: What is the
feasibility of implementing effective sodium reduction strategies to treat hypertension in
primary care settings? A systematic review. Journal of Hypertension 2014, 32(7):13881394; discussion 1394.
52.
Liang H, Ma Z, Peng H, He L, Hu Z, Wang Y: CXCL16 deficiency attenuates renal injury
and fibrosis in salt-sensitive hypertension. Scientific Reports 2016, 6:28715.
53.
Tahara A, Takasu T: Prevention of progression of diabetic nephropathy by the SGLT2
90
inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice. European Journal of
Pharmacology 2018, 830:68-75.
54.
Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, Diep H, Kett MM,
Samuel CS, Kemp-Harper BK et al: Pharmacological inhibition of the NLRP3
inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive
hypertension. Cardiovascular Research 2019, 115(4):776-787.
55.
Tian M, Tang L, Wu Y, Beddhu S, Huang Y: Adiponectin attenuates kidney injury and
fibrosis in deoxycorticosterone acetate-salt and angiotensin II-induced CKD mice.
American Journal of Physiology Renal Physiology 2018, 315(3):F558-f571.
56.
Song K, Stuart D, Abraham N, Wang F, Wang S, Yang T, Sigmund CD, Kohan DE,
Ramkumar N: Collecting duct renin does not mediate DOCA-salt hypertension or renal
injury. PloS One 2016, 11(7):e0159872.
57.
Leelahavanichkul A, Yan Q, Hu X, Eisner C, Huang Y, Chen R, Mizel D, Zhou H, Wright
EC, Kopp JB et al: Angiotensin II overcomes strain-dependent resistance of rapid CKD
progression in a new remnant kidney mouse model. Kidney International 2010,
78(11):1136-1153.
58.
Peng H, Carretero OA, Alfie ME, Masura JA, Rhaleb NE: Effects of angiotensinconverting enzyme inhibitor and angiotensin type 1 receptor antagonist in
deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene. Hypertension
(Dallas, Texas : 1979) 2001, 37(3):974-980.
59.
Schinner E, Wetzl V, Schlossmann J: Cyclic nucleotide signalling in kidney fibrosis.
International Journal of Molecular Sciences 2015, 16(2):2320-2351.
60.
Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, Miyata K, Yamada T:
A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,791
diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. The Journal of
Pharmacology and Experimental Therapeutics 2000, 295(1):255-260.
61.
Guabiraba R, Campanha-Rodrigues AL, Souza AL, Santiago HC, Lugnier C, AlvarezLeite J, Lemos VS, Teixeira MM: The flavonoid dioclein reduces the production of proinflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive
oxygen species. European Journal of Pharmacology 2010, 633(1-3):85-92.
62.
Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Espinoza F, Pons H, Vaziri ND:
Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal
damage. Kidney International 2005, 68(5):2131-2142.
63.
Bae EH, Kim IJ, Joo SY, Kim EY, Kim CS, Choi JS, Ma SK, Kim SH, Lee JU, Kim SW:
Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. Kidney & Blood
Pressure Research 2012, 36(1):248-257.
64.
Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, Na KR, Kim SY, Shin YT, Lee
KW: Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats.
American Journal of Physiology Renal Physiology 2009, 297(2):F362-370.
65.
Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY, Lim SJ: Effects of sildenafil on oxidative
and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. American
Journal of Nephrology 2009, 29(3):274-282.
66.
Gong K, Xing D, Li P, Hilgers RH, Hage FG, Oparil S, Chen YF: cGMP inhibits TGFbeta signaling by sequestering Smad3 with cytosolic beta2-tubulin in pulmonary artery
smooth muscle cells. Molecular Endocrinology (Baltimore, Md) 2011, 25(10):1794-1803.
67.
Zeng LF, Xiao Y, Sun L: A glimpse of the mechanisms related to renal fibrosis in diabetic
nephropathy. Advances in Experimental Medicine and Biology 2019, 1165:49-79.
68.
Zheng C, Huang L, Luo W, Yu W, Hu X, Guan X, Cai Y, Zou C, Yin H, Xu Z et al:
92
Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy
in STZ-induced diabetic mice. Cell Death & Disease 2019, 10(11):848.
69.
Tao Y, Han J, Liu W, An L, Hu W, Wang N, Yu Y: MUC1 promotes mesangial cell
proliferation and kidney fibrosis in diabetic nephropathy through activating STAT and βCatenin signal pathway. DNA and Cell Biology 2021, 40(10):1308-1316.
70.
Aroor AR, Habibi J, Nistala R, Ramirez-Perez FI, Martinez-Lemus LA, Jaffe IZ, Sowers
JR, Jia G, Whaley-Connell A: Diet-Induced Obesity Promotes Kidney Endothelial
Stiffening and Fibrosis Dependent on the Endothelial Mineralocorticoid Receptor.
Hypertension (Dallas, Texas : 1979) 2019, 73(4):849-858.
71.
Xu W, Zhao Y, Zhang B, Xu B, Yang Y, Wang Y, Liu C: Resveratrol attenuates hyperoxiainduced oxidative stress, inflammation and fibrosis and suppresses Wnt/β-catenin
signalling in lungs of neonatal rats. Clinical and Experimental Pharmacology &
Physiology 2015, 42(10):1075-1083.
72.
Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki
M, Verbeuren TJ et al: SIRT1 regulates hepatocyte lipid metabolism through activating
AMP-activated protein kinase. The Journal of Biological Chemistry 2008,
283(29):20015-20026.
73.
Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye
L, Ramadori G, Teodoro JS et al: SIRT1 is required for AMPK activation and the
beneficial effects of resveratrol on mitochondrial function. Cell Metabolism 2012,
15(5):675-690.
74.
Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R,
Brown AL et al: Resveratrol ameliorates aging-related metabolic phenotypes by
inhibiting cAMP phosphodiesterases. Cell 2012, 148(3):421-433.
93
75.
Chang JM, Kuo MC, Kuo HT, Chiu YW, Chen HC: Increased glomerular and
extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. The
Journal of Laboratory and Clinical Medicine 2005, 146(4):210-215.
76.
Abe Y, Sakairi T, Beeson C, Kopp JB: TGF-β1 stimulates mitochondrial oxidative
phosphorylation and generation of reactive oxygen species in cultured mouse podocytes,
mediated in part by the mTOR pathway. American Journal of Physiology Renal
Physiology 2013, 305(10):F1477-1490.
77.
Delaunay M, Osman H, Kaiser S, Diviani D: The role of cyclic AMP signaling in cardiac
fibrosis. Cells 2019, 9(1).
78.
Xu M, Li S, Wang J, Huang S, Zhang A, Zhang Y, Gu W, Yu X, Jia Z: Cilomilast
ameliorates renal tubulointerstitial fibrosis by inhibiting the TGF-β1-Smad2/3 signaling
pathway. Frontiers in Medicine 2020, 7:626140.
79.
Zeng QX, Jiang KL, Wu ZH, Huang DL, Huang YS, Zhuang HW, Zhong HJ: Pleural
effusion is associated with severe renal dysfunction in patients with acute pancreatitis.
Medical Science Monitor 2021, 27:e928118.
80.
Al-Harby A, Al-Furayh O, Al-Dayel F, Al-Mobeireek A: Pleural effusion in a patient with
end-stage renal disease. Annals of Saudi Medicine 2006, 26(2):145-146.
94
...
論文の公開元へ
